ABIVAX is trading at €80.15, with a -4.01% change; broader French-market weakness is the clearest available context for the decline.
- No verified ABIVAX-specific announcement explains the October 5 decline.
- French equities faced pressure from fiscal worries and political uncertainty. Reuters reported the CAC 40 fell 0.8% and the euro slid to a 17-month low.
- Available evidence does not establish a company-specific catalyst.